Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Pyxis Oncology, Inc. (PYXS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...|
Docs:
|
"Pyxis Oncology Successfully Completes Acquisition of Apexigen August 23, 2023 Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalimab CD40 agonist to be shared in 4Q23 BOSTON, Aug. 23, 2023 -- Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful c..." |
|
| 08/11/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The Merger On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation , entered into an Agreement and Plan of Merger , by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company , and Apexigen, Inc., a Delaware corporation , pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Apexigen , with Apexigen surviving such Merger as a wholly-owned subsidiary of the Company. Definitions for the capitalized terms used in this section are provided herein. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger : a) Each share of common stock, par value $0.0001 per share, of..." |
|
| 06/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/24/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Executed Version AGREEMENT AND PLAN OF MERGER Among Pyxis Oncology, Inc. Ascent Merger Sub Corp. And Apexigen, Inc. Dated as of May 23, 2023 Table of Contents Page Article I The Merger 1 Section 1.01. The Merger 1 Section 1.02. Closing 1 Section 1.03. Effective Time 2 Section 1.04. Effects 2 Section 1.05. Certificate of Incorporation and Bylaws 2 Section 1.06. Directors 2 Section 1.07. Officers 2 Article II Effect on the Shares of the Constituent Corporations; Exchange of Shares 3 Section 2.01. Effect on Shares 3 Section 2.02. Exchange of Shares 4 Section 2.03. Company Equity Awards; ESPP 7 Section 2.04. Company Warrants 9 Article III Representations and Warranties of the Company 9 Section 3.01. Organization and Qualification; Subsidiaries 9 Section 3.02. Certificate of Incorporation and B...",
"VOTING AGREEMENT This Voting Agreement is being delivered on May 23, 2023 by the person or persons named on the signature pages hereto , as the holder of Company Shares of Apexigen, Inc., a Delaware corporation , to Pyxis Oncology, Inc., a Delaware corporation . Reference is made to that certain Agreement and Plan of Merger , dated as of the date hereof, by and among the Company, Parent and Merger Sub, a form of which has been provided to the Holder. All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. As of the date hereof, the Holder is the beneficial owner of the number of shares of Company Common Stock and other securities convertible into, or exercisable or exchangeable for, shares of Company Common Sto...",
"Pyxis Oncology to Acquire Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025; PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON, Mass. & SAN CARLOS, Calif., May 24, 2023 – Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers,..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash and short-term investments and no debt supports operations into 1H 2025 BOSTON, Mass., May 11, 2023 – Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2023, and provided a corporate update. Pyxis Oncology ended the first quarter of 2023 with approximately $150.8 million in cash, cash equivalents, restricted cash and short-term investments, which is expect..." |
|
| 03/28/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Interactive Data |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 04/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/29/2022 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/15/2021 |
8-K
| Quarterly results|
Docs:
|
"Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update CAMBRIDGE, Mass., Nov. 15, 2021 – Pyxis Oncology, Inc. , a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and provided a business update. “Our initial public offering was a tremendous milestone for Pyxis, allowing us to debut as a public company with a strong balance sheet well positioned to advance our lead programs toward the clinic,” said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. “We are on track to submit Investigational New Drug applications for PYX-201 and PYX-202 by mid-2022, and for PYX-203 by 2023. With the resource..." |
|
|
|